Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

PURPOSE: One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 (Alliance), a 2 × 2 factorial, open-label, randomized phase II trial, evaluated the impact of adding carboplatin and/or bevac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Sikov, William M., Berry, Donald A., Perou, Charles M., Singh, Baljit, Cirrincione, Constance T., Tolaney, Sara M., Kuzma, Charles S., Pluard, Timothy J., Somlo, George, Port, Elisa R., Golshan, Mehra, Bellon, Jennifer R., Collyar, Deborah, Hahn, Olwen M., Carey, Lisa A., Hudis, Clifford A., Winer, Eric P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4268249/
https://ncbi.nlm.nih.gov/pubmed/25092775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.0572
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados